41 results about "Nephron" patented technology

The present invention relates to bioartificial devices and systems that mimic kidney or nephron function and methods of making them.

Disclosed are compositions, methods and kits to control bleeding through the use of an internal occluder based on polymeric solutions, including use of reverse thermosensitive polymers in nephron-sparing surgeries, which produces a completely bloodless surgical field, allowing speedy resection. In certain embodiments, after a certain amount of time, the flow gradually resumes, with no apparent adverse consequences to the kidney. In certain embodiments, return of blood flow may be accelerated by cooling the kidney. The compositions, methods and kits for perfusive organ hemostasis can also be used to simplify or to enable other organ surgeries or interventional procedures, including liver surgery, prostate surgery, brain surgery, surgery of the uterus, spleen surgery and any surgery on any highly vascularized organs.

A 3D printed tubular construct, such as a nephron, with or without embedded vasculature as well as methods of printing tubular tissue constructs are described.

The invention relates to an oyster peptide beverage, which consists of oyster peptide, fish collagen peptide, silkworm amino acid, a ginseng extracting solution, isomaltooligosaccharide, zinc gluconate, white sugar and the balance of water. The beverage prepared by the invention is rich in easily absorbable active oligopeptide, ginseng extract, amino acid, prebiotics and trace elements; the beverage is rich in nutrition; and the various components are combined to develop coordinating and reinforcing effects on the oyster peptide, so that the finished product is capable of enhancing body function, promoting metabolism, promoting generation of essence and marrow and nourishing nephrons, and the product, as being taken for a long time, is capable of nourishing and strengthening body.

The invention belongs to the technical field of medical apparatuses and instruments, and provides a self-locking type half kidney loop ligature for a minimally invasive surgery. The self-locking type half kidney loop ligature for the minimally invasive surgery is formed by a kidney ligature (1), a hoop (2), a connecting rod handle (3), a hoop clamping sheet (4), a self-locking pull sheet (5), a self-locking sliding block (6), a sliding block clamping sheet (7) and a movable handle (8). According to the self-locking type half kidney loop ligature for the minimally invasive surgery, by means of controlling the kidney ligature (1), only the blood supply of the kidney of a tumor growth end can be cut off, the effect of tumor removal is guaranteed, blood loss volume in the surgery process is reduced, and most importantly, the ischemia time of reserved parts of the kidney is reduced to zero; the fact that blocking on the blood supply of the whole kidney is avoided, the functions of the reserved parts of the kidney are protected to the maximum extent, and the significance of nephron-sparing surgeries under a peritoneoscope is fully embodied.

The present invention relates to a method for treating the kidney with extracorporeal shockwaves in a noninvasive manner and in particular, to such a method for the treatment of the nephrons about the glomerulus.

Embodiments of the invention relate generally to methods of identifying subjects likely to develop diabetes-associated damage to the nephron, or subjects in the early stages of diabetic nephropathy. In particular, several embodiments relate to quantification of diabetic nephropathy-associated markers by isolating RNA isolated from vesicles from patient urine samples. The levels of the marker in a subject can be compared to levels in a population having normal nephron function and/or used to to track progression of diabetic nephropathy in said subject over time.

Described herein are methods related to generating intermediate mesoderm (IM) cells, including using sequential treatment of small molecules and growth factors, and composition produced by the described methods. Using small molecules such as CHIR99021 in combination with FGF2 and RA, efficient differentiation of human pluripotent stem cells (hPSCs) into intermediate mesoderm, such as PAX2+LHX1+ cells, is achieved. The method is extensible different hPSC cell lines and does not require flow sorting. Importantly, resulting PAX2+LHX1+ cells, are capable of WT1 expression and addition of FGF9 and activin, PAX2+LHX1+ cells specifically differentiates cells into SIX2, SALL1, and WT1 expressing cells representative of cap mesenchyme nephron progenitor cells. The described methods and compositions facilitate and improve the directed differentiation of hPSCs into cells of the kidney lineage for the purposes of bioengineering kidney tissue and iPS cell disease modeling.

The invention discloses sugar-free physique-strengthening beef bone soup. The sugar-free physique-strengthening beef bone soup comprises, by weight, 1800-2200 parts of beef sternum, 1900-2300 parts of beef ribs, 50-65 parts of sharpleaf galangal fruit, 110-130 parts of mulberry, 35-42 parts of peach seed, 75-85 parts of Chinese yam, 55-66 parts of Chinese date, 28-33 parts of Chinese cabbage, 32-38 parts of broccoli, 18-25 parts of cabbage ball, 26-35 parts of tomato, 36-42 parts of carrot, 8-11 parts of capsicum, 9-13 parts of Chinese prickly ash and 26-30 parts of spinach. The sugar-free physique-strengthening beef bone soup is convenient for eating, has scientific and reasonable nutritive composition, has effects of tonifying nephron, nourishing stomach and invigorating spleen, promoting bone development, and improving physical power and strengthening physique, and is especially suitable for being eaten by high-mental consumption and high-physical consumption people such as students, athletes and designers and people having weak physique.

The invention discloses a Chinese medicament for treating kidney failure. The Chinese medicament comprises the following components in parts by mass: 20 to 24 parts of rosa laevigata michx, 9 to 15 parts of Gordon Euryale seeds, 7 to 11 parts of poison yams, 15 to 16 parts of lalang grass rhizome, 100 to 120 parts of cirsium japonicum, 100 to 120 parts of common cephalanoplos herb, 1 to 3 parts of sanguisorba officinalis, 40 to 80 parts of Chinese arborvitae twig, 15 to 30 parts of blighted wheat, 3 to 5 parts of prepared rhizome of rehmannia, 30 to 50 parts of angelica, 5 to 10 parts of tuber fleeceflower stems, 20 to 30 parts of jujube kernels, 19 to 20 parts of concha haliotidis, 10 to 20 parts of chrysanthemum, 10 to 20 parts of pepperweed seeds, 9 to 15 parts of cortex phellodendri and 25 to 27 parts of atractylodes lancea. The Chinese medicament for treating kidney failure aims to arouse an immune function of a human body, promote the self-healing capability of the human body, discharge metabolic waste of the human body, protect organs from being damaged by toxins produced by the organs, keep residual nephrons and promote regeneration of nephrons, thereby treating kidney failure.

The invention belongs to the technical field of traditional Chinese medicine preparation and discloses a radix angelicae sinensis and radix astragali treatment reagent for treating early diabetic nephropathy and a preparation method. The reagent is prepared from 10-15 parts of radix angelicae sinensis, 8-11 parts of radix astragali, 5-8 parts of poria cocos, 3-5 parts of radix ginseng, 3-6 parts of radix codonopsis, 7-10 parts of rhizoma atractylodis macrocephalae, 2-4 parts of corn stigma, 6-10 parts of dried orange peel, 10-12 parts of rhizoma cimicifugae, 10-13 parts of radix bupleuri, 8-10parts of radix glycyrrhizae, 15-20 parts of polished round-grained rice, 12-15 parts of rhizoma anemarrhenae, 4-8 parts of radix ophiopogonis, 11-15 parts of radix puerariae, 10-15 parts of radix rehmanniae preparata, 9-13 parts of achyranthes roots, 10-15 parts of plantain herb and 6-10 parts of rhizoma chuanxiong. The reagent can enrich and activate blood, relieve restlessness, soothe nerves, protect the kidney, reduce damage of nephron, increase renal blood flow, improve the creatinine clearance rate, reduce urea nitrogen, relieve acute renal failure, protect the kidney, reduce blood sugar, reduce proteinuria and relieve renal toxic damage caused by gentamicin.

The invention relates to the field of stem cell biology, in particular to a kidney epithelial cell and a preparation method and application thereof. The first disclosed kidney epithelial cell expresses CDH1<+> and PODXL<+>, and at least expresses one of CDH2<+> and LTL<+>. The second disclosed preparation method of the kidney epithelial cell includes the following steps that pluripotent stem cellsare differentiated into posterior streak cells; the posterior streak cells are differentiated into posterior intermediate mesoderms; the posterior intermediate mesoderms are differentiated into kidney progenitor cells; the kidney progenitor cells are differentiated into kidney tubular aggregated precursors; the kidney tubular aggregated precursors are differentiated into kidney vesicles; and thekidney vesicles are differentiated into kidney epithelial cells. The provided preparation method has high differentiation efficiency and stable differentiation effect, and is applied to a variety of hPSC cell lines; and the differentiated nephron progenitor cells can meet the requirements of kidney disease model building, kidney drug toxicity testing, kidney disease related drug screening and other scientific research experiment.

The invention relates to a hematodialysis concentrate for improving the residual renal function. The hematodialysis concentrate comprises a hematodialysis concentrate and drugs for promoting blood circulation and removing stasis, and the drugs are ligustrazine, vinpocetine or nimodipine. The hematodialysis concentrate inhibits tubular atrophy and proliferation of fibrous tissues and promotes reversion of disused nephron, improves the blood flow and increases the excretion rate of the renal tubule and the fibrous protein solution, improves blood flow volume of internal arteriovenous fistula, protects the lifeline of a hemodialysis patient, and improves the residual renal function of the residual renal function. The drugs directly permeate to a blood zone from a dialysate zone of a dialyzerin each dialysis treatment and play the roles in preventing platelet aggregation and reducing viscosity of blood in the blood zone, so that a hollow fiber of the dialyzer and a micropore of a dialysismembrane are not easy to block, the effective area for dialysis is kept, the micropore of the dialysis membrane is kept smooth, and the metabolic waste in the blood zone is fully dialyzed and cleared. The hematodialysis concentrate has the functions and effects of expanding arteriole and improving microcirculation and the renal function, and the residual nephron is protected, and the function isimproved.

The invention relates to a traditional Chinese medicine for treating nephrotic syndrome, comprising the following components by weight portion: 90-150 portions of umbellate pore furgus, 50-90 portions of mangnolia officinalis, 10-60 portions of unprocessed rhizoma pinelliae, 10-60 portions of ginseng and 10-60 portions of ligusticum wallichii. The traditional Chinese medicine is prepared from hundreds of selected traditional Chinese medicines, has reasonable collocation and accurate medication, achieves the purposes of supporting healthy energy and treating the primary and the secondary aspects at the same time through the function of mutual cooperation among the medicines, and does not have any toxic or side effect. The invention adjusts the systemic immune function by tonifying the kidney, invigorating blood circulation and expelling toxin, restores glomerular basement membrane, eliminates immune complex, lightens or eliminates urokinase protein and occult blood, promotes renal microcirculation, fastens renal metabolism, actives renal units, enables kidney to restore normal size, strengthens detoxification function, and enables toxin of serum creatinine, urea nitrogen, and the like to be exhausted from urine.

The invention discloses a method for making a kidney-specific drug delivery model. Compared with the prior art, the invention facilitates the reverse diffusion of the drug or the virus vector carrying the target gene through the renal pelvis, and uniformly reaches all the kidneys of the used nephron. Small tubules and glomerular capsules, drugs or target genes form a uniform therapeutic high concentration in the local kidney, and have less impact on extrarenal tissues and organs. It is an ideal kidney-targeted drug delivery method and is conducive to efficient research on chronic kidney disease. Therapeutic targets and pathogenesis. Compared with other current methods, it has the advantages of simple operation, good organ specificity, uniform distribution of drug (gene) in organs, controllable concentration, and small extrarenal impact.

There is no specific cure for chronic kidney disease (CKD), which affects one in every ten adults. The unmet medical need has created significant interest in regenerative therapeutic approaches. Described herein is a radically new and innovative therapeutic approach identified by characterizing a novel mechanism of renal tissue repair and its role in glomerular injury. By targeting this mechanism in CKD, significant therapeutic benefit supported by rapid cellular remodeling of kidney tissues, coincident with structural and functional nephron regeneration. Methods and compositions for achieving the described therapeutic approach are fundamentally different from existing strategies.